Clinical trial · Interventional
Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety
Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L, Crataegus oxyacantha and Salix alba L in mild and moderate anxiety. Clinical study phase III, multicenter, prospective, open. Patients will be included in sufficient quantity to achieve the minimum number of 124 evaluable patients.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anxiety | — | UNRESOLVED | — |
| Efficacy | — | UNRESOLVED | — |
| Tolerability | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Passiflora, Crataegus e Salix | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Liquid and solid
- interventionNames
- Drug: Passiflora, Crataegus e Salix
Primary outcomes (1)
- measure
- Hamilton Scales
- timeFrame
- 30 days
Secondary outcomes (1)
- measure
- Safety evaluation by adverse events relate.
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who achieve scores between 18 and 29 points in the Hamilton Scale for Anxiety; * Individuals of any ethnic group male and female, aged above 18 years; * Consent of the subject of research (a consent form signed). Exclusion Criteria: * Patients with known hypersensitivity to any components of the formula; * Pregnant women and nursing mothers; * Patients with endogenous depression, schizophrenia, suicidal tendency; * Patients with heart disease unabated, unabated kidney, liver and lung unabated unabated, at the discretion of the investigator; * Addiction to drugs, including alcohol, at the discretion of the investigator; * Patients who are using any medication that could interfere with the effect of the drug under study; * Impossibility of compliance to the protocol
References
Publications (0)
Data not yet available